ES2719776T3 - Inhibidores de GSK3 y métodos de uso de los mismos - Google Patents
Inhibidores de GSK3 y métodos de uso de los mismos Download PDFInfo
- Publication number
- ES2719776T3 ES2719776T3 ES13780300T ES13780300T ES2719776T3 ES 2719776 T3 ES2719776 T3 ES 2719776T3 ES 13780300 T ES13780300 T ES 13780300T ES 13780300 T ES13780300 T ES 13780300T ES 2719776 T3 ES2719776 T3 ES 2719776T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- compound
- group
- certain embodiments
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1*C(C)CC1 Chemical compound CC1*C(C)CC1 0.000 description 12
- TYYMYGWTBNTQHZ-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C(F)(F)F)c2C2c3cc(F)ccc3F)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C(F)(F)F)c2C2c3cc(F)ccc3F)=C2C1=O TYYMYGWTBNTQHZ-UHFFFAOYSA-N 0.000 description 1
- DCAIFVKDYWYHDP-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C)c2C2(C)c3cccc(C(N)=O)c3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C)c2C2(C)c3cccc(C(N)=O)c3)=C2C1=O DCAIFVKDYWYHDP-UHFFFAOYSA-N 0.000 description 1
- GQFUYSHWMLTFPZ-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccc(C)cc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccc(C)cc3)=C2C1=O GQFUYSHWMLTFPZ-UHFFFAOYSA-N 0.000 description 1
- YCEJJWWUCHXBOX-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccn[nH]3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C)c2C2c3ccn[nH]3)=C2C1=O YCEJJWWUCHXBOX-UHFFFAOYSA-N 0.000 description 1
- CNKCQXIXZDUWHE-QFIPXVFZSA-N CC(C)(C1)CC(Nc2n[nH]c(C3CC3)c2[C@@]2(C)c3cc(C(F)(F)F)ccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]c(C3CC3)c2[C@@]2(C)c3cc(C(F)(F)F)ccc3)=C2C1=O CNKCQXIXZDUWHE-QFIPXVFZSA-N 0.000 description 1
- IMKJGRXMBFNOGA-UHFFFAOYSA-N CC(C)(C1)CC(Nc2n[nH]cc2C2(C)c3ccccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]cc2C2(C)c3ccccc3)=C2C1=O IMKJGRXMBFNOGA-UHFFFAOYSA-N 0.000 description 1
- IMKJGRXMBFNOGA-LJQANCHMSA-N CC(C)(C1)CC(Nc2n[nH]cc2[C@@]2(C)c3ccccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]cc2[C@@]2(C)c3ccccc3)=C2C1=O IMKJGRXMBFNOGA-LJQANCHMSA-N 0.000 description 1
- IMKJGRXMBFNOGA-IBGZPJMESA-N CC(C)(C1)CC(Nc2n[nH]cc2[C@]2(C)c3ccccc3)=C2C1=O Chemical compound CC(C)(C1)CC(Nc2n[nH]cc2[C@]2(C)c3ccccc3)=C2C1=O IMKJGRXMBFNOGA-IBGZPJMESA-N 0.000 description 1
- MIVPKTHOMGOFRR-LURJTMIESA-N CC[C@H](C)C[NH+](C)[O-] Chemical compound CC[C@H](C)C[NH+](C)[O-] MIVPKTHOMGOFRR-LURJTMIESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713314P | 2012-10-12 | 2012-10-12 | |
| US201361779394P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/064716 WO2014059383A1 (en) | 2012-10-12 | 2013-10-11 | Gsk3 inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2719776T3 true ES2719776T3 (es) | 2019-07-16 |
Family
ID=49474737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13780300T Active ES2719776T3 (es) | 2012-10-12 | 2013-10-11 | Inhibidores de GSK3 y métodos de uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9096594B2 (enExample) |
| EP (1) | EP2909204B1 (enExample) |
| JP (2) | JP6321662B2 (enExample) |
| CA (1) | CA2887701C (enExample) |
| CY (1) | CY1122601T1 (enExample) |
| DK (1) | DK2909204T3 (enExample) |
| ES (1) | ES2719776T3 (enExample) |
| HR (1) | HRP20190406T1 (enExample) |
| HU (1) | HUE043853T2 (enExample) |
| LT (1) | LT2909204T (enExample) |
| PL (1) | PL2909204T3 (enExample) |
| PT (1) | PT2909204T (enExample) |
| RS (1) | RS58700B1 (enExample) |
| SI (1) | SI2909204T1 (enExample) |
| SM (1) | SMT201900136T1 (enExample) |
| WO (1) | WO2014059383A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9096594B2 (en) | 2012-10-12 | 2015-08-04 | The Broad Institute, Inc. | Kinase inhibitors and methods of use thereof |
| BR112015023261A2 (pt) | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições e métodos para expansão e cultura de células-tronco epiteliais |
| US10004751B2 (en) | 2014-07-10 | 2018-06-26 | The J. David Gladstone Institutes | Compositions and methods for treating Dengue virus infection |
| KR102493376B1 (ko) | 2014-09-03 | 2023-01-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법 |
| WO2016061344A1 (en) * | 2014-10-15 | 2016-04-21 | Mirx Pharmaceuticals Llc | Gsk3 inhibitors and their uses |
| JP2019506153A (ja) | 2016-01-08 | 2019-03-07 | マサチューセッツ インスティテュート オブ テクノロジー | 分化した腸内分泌細胞およびインスリン産生細胞の作製 |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| CA3048220A1 (en) | 2016-12-30 | 2018-07-05 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| WO2018187630A1 (en) * | 2017-04-05 | 2018-10-11 | The Broad Institute, Inc. | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
| US11331313B2 (en) | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
| CN110407769B (zh) * | 2018-04-27 | 2022-11-08 | 复旦大学 | 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途 |
| WO2019236703A1 (en) | 2018-06-05 | 2019-12-12 | Actuate Therapeutics Inc. | Methods of treating malignant lymphoproliferative disorders |
| US20210299233A1 (en) * | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
| CA3109647A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| EP3837351A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| AU2020218366A1 (en) | 2019-02-08 | 2021-09-16 | Frequency Therapeutics, Inc. | Valproic acid compounds and Wnt agonists for treating ear disorders |
| US20230014430A1 (en) * | 2019-11-20 | 2023-01-19 | Washington University | Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof |
| WO2023056463A1 (en) * | 2021-09-30 | 2023-04-06 | Trustees Of Tufts College | Glycogen synthase kinase 3 (gsk3) inhibitors for treating ctnnb1 syndrome |
| WO2024081939A2 (en) * | 2022-10-13 | 2024-04-18 | The Broad Institute, Inc. | Glycogen synthase kinase 3 inhibitors and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2024259178A1 (en) | 2023-06-14 | 2024-12-19 | The Broad Institute, Inc. | Glycogen synthase kinase 3 inhibitors and uses thereof |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2722416A1 (de) | 1977-05-18 | 1978-11-30 | Thomae Gmbh Dr K | Neue thiazolo-pyridine |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| JPH05157164A (ja) | 1991-12-03 | 1993-06-22 | Aisin Aw Co Ltd | 車両用自動変速機のサーボ油圧制御装置 |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| AU690906B2 (en) | 1993-04-08 | 1998-05-07 | Du Pont Pharmaceuticals Company | Novel polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disoders |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5750528A (en) | 1995-02-01 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| TW526202B (en) | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
| EP1355909A2 (en) * | 2001-02-02 | 2003-10-29 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| US6977262B2 (en) | 2001-02-02 | 2005-12-20 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| DE10121217A1 (de) | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| US7067507B2 (en) | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
| EP1648463A2 (en) * | 2003-06-13 | 2006-04-26 | Zentaris GmbH | Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| RS51351B (sr) * | 2005-07-20 | 2011-02-28 | Aventis Pharma S.A. | 1,4-dihidropiridin-kondenzovani hterocikli, postupci za njihovo dobijanje, upotreba i kompozicije koje ih sadrže |
| WO2008016123A1 (en) | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| US8778986B1 (en) | 2007-01-25 | 2014-07-15 | University Of South Florida | Treatment of glycogen synthase kinase-based disease |
| US20090181986A1 (en) | 2007-07-05 | 2009-07-16 | Matthew Abelman | Substituted heterocyclic compounds |
| US9265764B2 (en) | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
| FR2945535B1 (fr) * | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| DE102011106990B3 (de) | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| TW201406758A (zh) | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| US20160375006A1 (en) | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| US9096594B2 (en) | 2012-10-12 | 2015-08-04 | The Broad Institute, Inc. | Kinase inhibitors and methods of use thereof |
| JP2014139870A (ja) * | 2013-01-21 | 2014-07-31 | Hitachi Consumer Electronics Co Ltd | 照明装置およびこれを用いた映像表示装置 |
| WO2015087996A1 (ja) | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | イミダゾピリジン誘導体 |
| KR101602559B1 (ko) | 2014-04-29 | 2016-03-10 | 경북대학교 산학협력단 | 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도 |
| US10437707B2 (en) * | 2015-03-19 | 2019-10-08 | Teachers Insurance And Annuity Association Of America | Evaluating and presenting software testing project status indicators |
| WO2018187630A1 (en) | 2017-04-05 | 2018-10-11 | The Broad Institute, Inc. | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
-
2013
- 2013-10-11 US US14/052,661 patent/US9096594B2/en active Active
- 2013-10-11 HR HRP20190406TT patent/HRP20190406T1/hr unknown
- 2013-10-11 PL PL13780300T patent/PL2909204T3/pl unknown
- 2013-10-11 RS RS20190292A patent/RS58700B1/sr unknown
- 2013-10-11 ES ES13780300T patent/ES2719776T3/es active Active
- 2013-10-11 SM SM20190136T patent/SMT201900136T1/it unknown
- 2013-10-11 SI SI201331368T patent/SI2909204T1/sl unknown
- 2013-10-11 JP JP2015536972A patent/JP6321662B2/ja active Active
- 2013-10-11 WO PCT/US2013/064716 patent/WO2014059383A1/en not_active Ceased
- 2013-10-11 CA CA2887701A patent/CA2887701C/en active Active
- 2013-10-11 HU HUE13780300A patent/HUE043853T2/hu unknown
- 2013-10-11 EP EP13780300.3A patent/EP2909204B1/en active Active
- 2013-10-11 LT LTEP13780300.3T patent/LT2909204T/lt unknown
- 2013-10-11 DK DK13780300.3T patent/DK2909204T3/en active
- 2013-10-11 PT PT13780300T patent/PT2909204T/pt unknown
-
2015
- 2015-07-14 US US14/799,281 patent/US10137122B2/en active Active
-
2018
- 2018-04-05 JP JP2018072831A patent/JP6606691B2/ja active Active
- 2018-11-21 US US16/198,589 patent/US11052080B2/en active Active
-
2019
- 2019-03-05 CY CY20191100268T patent/CY1122601T1/el unknown
-
2021
- 2021-06-10 US US17/344,830 patent/US12419885B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018150302A (ja) | 2018-09-27 |
| SMT201900136T1 (it) | 2019-05-10 |
| JP6321662B2 (ja) | 2018-05-09 |
| US9096594B2 (en) | 2015-08-04 |
| WO2014059383A1 (en) | 2014-04-17 |
| CA2887701A1 (en) | 2014-04-17 |
| US20200061050A9 (en) | 2020-02-27 |
| CY1122601T1 (el) | 2021-03-12 |
| PL2909204T3 (pl) | 2019-07-31 |
| EP2909204A1 (en) | 2015-08-26 |
| DK2909204T3 (en) | 2019-04-01 |
| US10137122B2 (en) | 2018-11-27 |
| US20190175584A1 (en) | 2019-06-13 |
| US20150313890A1 (en) | 2015-11-05 |
| PT2909204T (pt) | 2019-03-21 |
| US11052080B2 (en) | 2021-07-06 |
| HUE043853T2 (hu) | 2019-09-30 |
| LT2909204T (lt) | 2019-05-10 |
| US20220160702A1 (en) | 2022-05-26 |
| HRP20190406T1 (hr) | 2019-05-31 |
| JP6606691B2 (ja) | 2019-11-20 |
| CA2887701C (en) | 2020-12-15 |
| US20140107141A1 (en) | 2014-04-17 |
| EP2909204B1 (en) | 2018-12-05 |
| US12419885B2 (en) | 2025-09-23 |
| JP2015536307A (ja) | 2015-12-21 |
| SI2909204T1 (sl) | 2019-06-28 |
| RS58700B1 (sr) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2719776T3 (es) | Inhibidores de GSK3 y métodos de uso de los mismos | |
| JP7200282B2 (ja) | サイクリン依存性キナーゼの阻害剤 | |
| CN104350055B (zh) | 作为mnk1和mnk2调节剂的二环杂芳基衍生物及其用途 | |
| CN110958882B (zh) | 作为糖原合酶激酶3(gsk3)抑制剂的三环化合物及其用途 | |
| US20160375006A1 (en) | Uses of paralog-selective inhibitors of gsk3 kinases | |
| KR20160111520A (ko) | 디히드로프테리디논 유도체 및 그의 용도 | |
| JP2018522867A (ja) | 縮合二環式ピリミジン誘導体およびこれらの使用 | |
| HK1256417A1 (zh) | 氰基噻吩並三唑並二氮雜環庚三烯及其用途 | |
| CN115515682B (zh) | 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
| HK40013946B (en) | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof | |
| HK40013946A (en) | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof | |
| WO2014036595A1 (en) | Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth | |
| HK1237593A1 (en) | Dihydropteridinone derivatives and uses thereof |